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Pulmonary Vein Isolation. Introduction: Based on the clinical history, paroxysmal atrial fibrillation
(PAF) may be classified as vagotonic, adrenergic, or random. It is unclear whether pulmonary vein (PV)
isolation is equally effective for these types of PAF.
Methods and Results: Segmental ostial ablation to isolate the PVs was performed in 188 consecutive
patients (mean age 53 ± 12 years) with PAF. Based on the clinical history, PAF was classified as random in
136 patients (72%), adrenergic in 30 (16%), and vagotonic in 22 (12%). Three or four PVs were targeted for
isolation in all patients, and successful isolation was achieved in 96% of targeted PVs. At 1-year follow-up,
69% of patients with random AF, 83% of patients with adrenergic AF, and 50% of patients with vagotonic
AF were free from recurrent episodes of AF in the absence of any antiarrhythmic drug therapy. Vagotonic
AF was an independent clinical predictor of recurrent AF (P = 0.03).
Conclusion: PV isolation has a lower efficacy in patients with vagotonic PAF than in patients with adren-
ergic or random episodes of PAF, suggesting that the PVs less often play an important role in vagotonic
PAF. (J Cardiovasc Electrophysiol, Vol. 15, pp. 402-405, April 2004)
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Introduction
In some patients, paroxysmal atrial fibrillation (PAF) may
occur during states of increased adrenergic activity, whereas
in others, PAF may occur during states of heightened vagal
tone.1-4 Based on the different autonomic milieu in which
they occur, adrenergic and vagotonic PAF may have differ-
ent mechanisms. Although pulmonary vein (PV) isolation
often is effective in eliminating PAF, prior studies have not
distinguished subgroups of PAF.5,6 Therefore, it is unclear
whether PV isolation has similar efficacy in patients with
vagotonic, adrenergic, and random episodes of PAF. The aim
of this study was to compare the long-term outcomes after PV




PV isolation was performed in 188 consecutive patients
with symptomatic, drug-refractory PAF. The clinical charac-
teristics of the patients are given in Table 1.
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Coumel et al.1,7 first described the syndromes of vago-
tonic and adrenergic PAF. In his studies, Coumel indicated
that these types of PAF can be reliably identified based on de-
tails of the clinical history; therefore, classification of PAF in
the present study was based on a detailed clinical history. Pa-
tients with PAF that occurred at least 90% of the time during
sleep or after dinner while patients were relaxing were classi-
fied as having vagotonic PAF. Patients with PAF that occurred
at least 90% of the time during or shortly after strenuous ex-
ertion or other states of adrenergic activation were classified
as having adrenergic PAF. Other patients in whom episodes
occurred predominantly on a random basis were described as
having random episodes of PAF.2-4
PV Isolation
All patients provided written informed consent. Electri-
cal isolation of the PVs was performed by segmental ostial
applications of radiofrequency energy, as described previ-
ously.5,6,8 The left superior, left inferior, and right superior
PVs were targeted in all 188 patients. The right inferior PV
also was targeted in 77 patients (41%). The percentage of
patients who underwent isolation of the right inferior PV did
not differ among the three subgroups (P = 0.8). Complete
isolation was achieved in 96% of targeted PVs, with no dif-
ferences between patients with vagotonic, adrenergic, and
random episodes of PAF.
After the ablation procedure, all patients underwent con-
tinuous monitoring for 24 hours. Heparin was adminis-
tered intravenously for 24 hours and was followed by low-
molecular-weight heparin for 4 days and warfarin for 1 to 3
months after the procedure.
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TABLE 1
Clinical Characteristics of Patients with Vagotonic, Adrenergic, and
Random PAF
Vagotonic Adrenergic Random
PAF PAF PAF P Value
N 22 30 136
Age (years) 55 ± 10 50 ± 12 53 ± 12 0.3
Gender (male/female) 19/3 27/3 107/29 0.3
Duration of PAF (years) 6 ± 5 6 ± 7 8 ± 8 0.3
Episodes per month 12 ± 11 16 ± 14 17 ± 17 0.5
LVEF 0.54 ± 0.05 0.55 ± 0.04 0.55 ± 0.04 0.4
Left atrial size (mm) 42 ± 6 39 ± 4 39 ± 5 0.2
Structural heart disease 4 (18%) 5 (17%) 13 (10%) 0.3
Continuous variables are expressed as mean ± SD.
Follow-Up
All patients were seen in an outpatient clinic 4 to 6 weeks
and every 3 to 6 months after the ablation procedure. When-
ever they reported symptoms, they were provided with an
event recorder to document the cause of symptoms. Because
episodes of PAF that occur within 4 weeks after PV isolation
may be transient, episodes of PAF that were limited to the
first month of follow-up were excluded from the analysis.9
During a mean duration of 445 ± 190 days, no patient was
lost to follow-up.
Statistical Analysis
Continuous variables are expressed as mean ± 1 SD and
were compared by Student’s t-test. Categorical variables were
compared by Chi-square analysis or with Fisher’s exact test.
Differences between continuous variables were determined
by analysis of variance. Kaplan-Meier analysis with the log
rank test was used to determine the probability of freedom
from recurrent PAF after PV isolation. Cox multivariate re-
gression analyses were performed to determine the clinical
predictors of freedom from PAF. P < 0.05 was considered
statistically significant.
Results
Modes of Onset of AF and Clinical Characteristics
Among the 188 patients, 22 (12%) were classified as hav-
ing vagotonic PAF, 30 (16%) were classified as having adren-
ergic PAF, and the remaining 136 patients (72%) were clas-
sified as having random episodes of PAF.
There were no significant differences with regard to age,
gender, duration of PAF, frequency of PAF, left ventricular
ejection fraction, left atrial size, or presence of structural heart
disease among the three subgroups of PAF (Table 1).
Freedom from Recurrent PAF
At 1-year follow-up, PV isolation resulted in freedom
from recurrent PAF in 50% of patients with vagotonic PAF
(Fig. 1). The percentage of patients free of recurrent PAF af-
ter PV isolation was higher among patients with adrenergic
PAF (83%, P = 0.02) and among patients with a history of
random episodes of PAF (69%, P = 0.05) compared to those
with vagotonic PAF. The percentage of patients free of PAF at
Figure 1. Freedom from paroxysmal atrial fibrillation (PAF) in patients
with vagotonic, adrenergic, and random PAF. The recurrences of PAF that
occurred only within the first month of follow-up were blanked out. P = 0.04
for vagotonic vs adrenergic AF; P = 0.07 for vagotonic vs random AF; P =
0.3 for random vs adrenergic AF (log rank test).
1-year follow-up did not differ significantly between patients
with adrenergic and random episodes of PAF (P = 0.3).
Multivariate Analysis of Predictors of Outcome
Among the clinical variables of age, gender, duration of
PAF, frequency of PAF, left ventricular ejection fraction, left
atrial size, presence of structural heart disease, and whether
or not the PAF was vagotonic, the only independent predictor
of recurrent episodes of PAF after PV isolation was vagotonic
PAF (P = 0.03). P values for the univariate and multivariate
analyses are listed in Table 2.
Discussion
Main Findings
The clinical syndromes of vagotonic and adrenergic PAF
were first described in anecdotal fashion 25 years ago,1 but
the prevalence of these types of PAF has never been de-
fined. In the present study of patients with drug-refractory
PAF referred for catheter ablation, the clinical history was
TABLE 2
P value for the Univariate and Multivariate Analyses of Clinical Predictors
of Recurrence of AF After PV isolation
P Value for P Value for
Univariate Multivariate
Analysis Analysis
Age (years) 0.1 0.4
Gender (male/female) 0.7 0.6
Duration of PAF (years) 0.02 0.05
Frequency of episodes of AF 0.5 0.7
LVEF 0.4 0.4
Left atrial size (mm) 0.9 0.5
Structural heart disease 0.9 0.7
Vagotonic AF 0.04 0.03
LVEF = left ventricular ejection fraction; PAF = paroxysmal atrial
fibrillation.
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characteristic of vagotonic and adrenergic PAF in 12% and
16% of patients, respectively.
PV isolation was found to be significantly less effective
among the patients with vagotonic PAF than among the pa-
tients with adrenergic or random episodes of PAF. This ob-
servation implies that the PVs less often serve as a key source
of triggers or drivers of atrial fibrillation in vagotonic PAF
than in other types of PAF.
Vagotonic PAF
An increase in vagal tone results in shortening of the atrial
effective refractory period, an increase in dispersion of re-
fractoriness, and an increase in the vulnerability to AF.8,10,11
In addition, vagal stimulation may increase the frequency
of premature atrial depolarizations from anywhere in the
atria.8,10,11 These effects of heightened vagal tone may ex-
plain why PV isolation is less often effective in eliminating
the vagotonic variety of PAF than other types of PAF. How-
ever, the fact that PV isolation was still effective in ∼50% of
patients with vagotonic AF suggests that the PVs play a role
in at least some patients with vagotonic AF. It also is possi-
ble that segmental ostial ablation has an effect on autonomic
innervation of the left atrium. In any case, to improve the ef-
ficacy of the procedure in patients with vagotonic AF, it may
be appropriate to consider ablation of non-PV triggers and/or
left atrial substrate modification in addition to PV isolation.
Adrenergic PAF
Prior experimental and clinical studies have suggested that
the vein of Marshall may play an important role in the ini-
tiation of adrenergically mediated episodes of atrial fibrilla-
tion.12,13 In the present study, patients with adrenergic PAF
responded favorably to PV isolation, without any attempts
to identify or ablate the vein of Marshall. However, because
the vein of Marshall may be located close to the left superior
PV,12 it is possible that some applications of radiofrequency
energy aimed at the ostium unintentionally also ablated the
insertion of the vein of Marshall. It also is possible that both
the PVs and the vein of Marshall play a role in generating
adrenergic PAF, but that isolation of the PVs by itself often
is sufficient to eliminate this type of PAF.
Clinical Predictors of Recurrent AF After PV Isolation
Vagotonic AF was the only independent predictor of re-
current episodes of AF among the clinical variables of age,
gender, duration of PAF, frequency of PAF, left ventricular
ejection fraction, left atrial size, presence of structural heart
disease, and whether or not the PAF was vagotonic. Although
the duration of AF also was a univariate predictor, in multi-
variate analysis, vagotonic AF emerged as a stronger inde-
pendent predictor. As reported previously,14 the duration of
AF may be one of the independent predictors for recurrences
of AF. However, in that study, vagotonic AF was not assessed
and was not incorporated into the analysis as a clinical vari-
able. The amount of left atrial electroanatomic remodeling
may increase with the duration of AF, and this may decrease
the relative importance of the PVs in the generation of AF.
However, in patients with vagotonic AF, the PVs may not be
as critical in the initiation and perpetuation of AF as in other
types of AF. Therefore, when vagotonic AF is also included
in a multivariate analysis, it may become more prominent
than the duration of AF, because vagotonic AF may indicate
the presence of a non-PV substrate for the AF.
Study Limitations
A limitation of this study is that there were no attempts
to identify asymptomatic episodes of PAF. Therefore, it is
possible that the efficacy of PV isolation was overestimated.
However, there would be no reason for asymptomatic PAF to
be less likely in patients with vagotonic PAF than in patients
with adrenergic or random PAF. Therefore, the lower efficacy
of PV isolation among patients with vagotonic PAF in all
likelihood still would be a valid finding.
In some patients, most but not all episodes of PAF occurred
during characteristic periods of heightened vagal or adrener-
gic tone. Allowing for the possibility of occasional random
episodes of PAF in patients with vagotonic or adrenergic PAF,
patients were included in the vagotonic and adrenergic sub-
groups if at least 90% of their episodes were consistent with
that type of PAF. This 90% cutoff was arbitrarily chosen and
was dependent on self-assessment by the patients. Detailed
logs of all episodes were not available.
The patients in this study were selected to undergo catheter
ablation because they had frequent, symptomatic, drug-
refractory episodes of PAF. The prevalence of vagotonic and
adrenergic PAF may be different in an unselected population
of patients with PAF.
Conclusion
In approximately 25% of patients with PAF, the clinical
history may be consistent with vagotonic or adrenergic PAF.
Identification of these subgroups of patients with PAF has
therapeutic implications. For example, in patients with vago-
tonic PAF, drugs that increase vagal tone, e.g., digitalis, may
make episodes of PAF more frequent. In contrast, among pa-
tients with adrenergic PAF, beta-blockers, which usually pro-
vide only control of the ventricular rate, may prevent episodes
of PAF.
The results of the present study suggest that identifica-
tion of vagotonic PAF has another therapeutic implication.
Whereas approximately 70% or more of patients with adren-
ergic or random episodes of PAF have an excellent outcome
1 year after PV isolation, this is the case in only 50% of pa-
tients with vagotonic PAF. Therefore, among potential can-
didates for PV isolation, if the clinical history indicates that a
patient has vagotonic PAF, it may be appropriate to consider
an alternative ablation strategy.14
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